

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Pharmaron Beijing Co., Ltd.**

**康龍化成(北京)新藥技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3759)**

**(1) CHANGE OF COMPANY SECRETARY,  
AUTHORISED REPRESENTATIVE AND PROCESS AGENT;  
(2) PROPOSED INCREASE IN REGISTERED CAPITAL; AND  
(3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

**I. CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

The board of directors (the “**Board**”) of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “**Company**”) hereby announces that Mr. Yim Lok Kwan (“**Mr. Yim**”) has tendered his resignation as the company secretary of the Company (the “**Company Secretary**”) and will cease to act as an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the process agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from March 30, 2026.

Mr. Yim has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and the Stock Exchange.

Following the resignation of Mr. Yim, the Board further announces that Ms. Mak Po Man Cherie (“**Ms. Mak**”) has been appointed as the Company Secretary, an Authorised Representative and the Process Agent with effect from March 30, 2026.

The biographical details of Ms. Mak are set out below:

Ms. Mak is the Vice President of SWCS Corporate Services Group (Hong Kong) Limited. She has worked for various professional firms and listed companies in Hong Kong, with over 20 years of experience in the fields of audit, accounting, corporate finance, compliance and corporate secretarial matters. Ms. Mak obtained a Master of Corporate Governance degree from The Hong Kong Polytechnic University in 2017. She was admitted as an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in 2017, a member of the Hong Kong Institute of Certified Public Accountants in 2003, and a fellow member of the Association of Chartered Certified Accountants in 2006.

The Board would like to take this opportunity to express its gratitude to Mr. Yim for his contribution to the Company during his tenure of service and to welcome Ms. Mak on her new appointment.

## II. PROPOSED INCREASE IN REGISTERED CAPITAL AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board has resolved and approved, among others: (i) the proposed increase in the registered capital of the Company; and (ii) the proposed amendments to the articles of association of the Company (the “**Articles of Association**”).

By reason of (i) the Company’s placing of a total of 58,440,762 new H shares on January 22, 2026; and (ii) the completion of registration and circulation of a total of 647,341 restricted A shares vested respectively under the fourth vesting period of the 2021 A Share Incentive Scheme and the third vesting period of the 2022 A Share Incentive Scheme on January 29, 2026, the Board proposed to change the registered capital of the Company from RMB1,778,195,525 (divided into 1,778,195,525 shares) to RMB1,837,283,628 (divided into 1,837,283,628 shares).

By virtue of the increase in the registered capital of the Company, the Board resolved and approved, among others, the following proposed amendments (collectively, the “**Proposed Amendments**”) to the Articles of Association:

<b>Before Amendment</b>	<b>After Amendment</b>
<b>Article 6</b> The registered capital of the Company is Renminbi (RMB) <b>1,778,195,525</b> .	<b>Article 6</b> The registered capital of the Company is Renminbi (RMB) <b>1,837,283,628</b> .
<b>Article 21</b> The shareholding structure of the Company is <b>1,778,195,525</b> ordinary shares, including <b>1,476,658,400</b> shares held by holders of A Shares, and <b>301,537,125</b> shares held by holders of H shares.	<b>Article 21</b> The shareholding structure of the Company is <b>1,837,283,628</b> ordinary shares, including <b>1,477,305,741</b> shares held by holders of A Shares, and <b>359,977,887</b> shares held by holders of H shares.

Save for the Proposed Amendments, other provisions of the Articles of Association shall remain unchanged. The Proposed Amendments to the Articles of Association are prepared in Chinese. In the event of any discrepancy between the English translation and the Chinese version, the Chinese version shall prevail.

The Board has also resolved to propose a resolution at the AGM to authorize the Company’s legal representative and their authorized persons to handle the approval and filing procedures with relevant regulatory authorities involved in such amendments, and to make such adjustments to the wording of such amendments to the Articles of Association according to opinions of the regulatory authorities. The Proposed Amendments to the Articles of Association are ultimately subject to the results approved by relevant regulatory authorities. Prior to the Proposed Amendments to the Articles of Association being approved by way of special resolution at the AGM, the existing Articles of Association shall remain valid.

### III. GENERAL

The Board considers that the said increase in the registered capital of the Company and the Proposed Amendments are in the interests of the Company and the Shareholders as a whole. The proposed increase in the registered capital of the Company and the Proposed Amendments are subject to the consideration and approval by the Shareholders by way of special resolution at the AGM.

A circular containing, among other things, details about the proposed increase in the registered capital of the Company and the Proposed Amendments will be despatched to the Shareholders as soon as practicable.

By order of the Board  
**Pharmaron Beijing Co., Ltd.**  
康龍化成(北京)新藥技術股份有限公司  
**Dr. Lou Boliang**  
*Chairman*

Beijing, the PRC  
March 30, 2026

*As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Shing Chung Gilbert as employee representative Director; Mr. Li Jiaqing and Ms. Wan Xuan as non-executive Directors; Ms. Li Lihua, Prof. Tsang King Fung and Mr. Yu Jian as independent non-executive Directors.*